scholarly journals Livello di dipendenza dai Servizi Territoriali e costi relativi al trattamento della schizofrenia

2005 ◽  
Vol 6 (4) ◽  
pp. 301-304
Author(s):  
Giorgio D’Allio ◽  
Fernando Rutto ◽  
Michela Coppi ◽  
Luca Guidi
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Health Care Costs ◽  
Chronic Conditions ◽  
Home Intervention ◽  
One Year ◽  
Care Costs ◽  
Home Nurse ◽  
Nurse Intervention ◽  
Typical Neuroleptics

The present study was designed to evaluate the level of dependence from Mental Health Care Department, in Casale Monferrato, of three groups of psychotic patients treated with olanzapine (31), risperidone (30) or typical neuroleptics (31). The observation was retrospective, lasting one year (2003-2004), and collected data relative to health care resources as specialist visits, home interventions operated by nurses or physicians, drug administration, rehabilitation, psychotherapy, hospitalizations. The data collected allowed to evidentiate substantial differences among olanzapine and risperidone treated patients, usually younger, versus typical treated patients, usually older and more chronic. In general, atypical treated patients, evidentiate a reduction of home nurse intervention in respect to typical treated patients while olanzapine shows a trend in hospitalization and specialist visits reduction versus risperidone. Total health care costs are not significantly different among the three groups but evidentiate interventions more oriented to rehabilitation in the group treated with olanzapine while risperidone treated patients needed a major number of hospitalizations. Typical treated patients requested, instead, an high number of home intervention due to their chronic conditions and cognitive imparement.

All-cause and disease-related health care costs associated with recurrent venous thromboembolism

2013 ◽  
Vol 110 (12) ◽  
pp. 1288-1297 ◽  
Author(s):  
Patrick Lefebvre ◽  
Edith A. Nutescu ◽  
Mei Duh ◽  
Joyce LaMori ◽  
Brahim K. Bookhart ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Propensity Scores ◽  
Venous Ulcer ◽  
P Value ◽  
Cost Difference ◽  
Recurrent Venous Thromboembolism ◽  
Recurrent Vte ◽  
One Year ◽  
Care Costs

SummaryIt was the objective of this study to quantify the risk of complications and the incremental health care costs associated with recurrent VTE events. Health care insurance claims from the Ingenix IMPACT database from 01/2004−09/2008 were analysed. Subjects aged ≥18 years on the date of first recurrent VTE diagnosis with ≥12 months of baseline observation prior to the index recurrent VTE were matched 1:1 with no-recurrent VTE patients based on propensity scores. The risk of developing post-thrombotic syndrome (PTS) and other disease-related diagnoses (thrombocytopenia, superficial venous thrombosis, venous ulcer, pulmonary hypertension, stasis dermatitis, and venous insufficiency) was compared between the recurrent and no-recurrent VTE groups for up to one year. All-cause and disease-related costs per patient per year (PPPY) were calculated. The recurrent VTE and no-recurrent VTE cohorts (8,001 subjects in each group) were matched with respect to age, gender, and comorbidities. The risk ratios (RRs) indicated that the risk of developing post-event complications was significantly higher for the recurrent VTE group compared to the no-recurrent VTE group (RR [95% CI]: PTS: 2.7 [2.4 − 2.9], p-value <0.01). Patients with recurrent VTE had significantly higher average PPPY all-cause costs compared to no-recurrent VTE patients ($86,744 versus $37,525, cost difference: $49,219 [€33,617]; 95% CI= 46,253−51,989). Corresponding disease-related health care costs PPPY were also significantly higher for the recurrent VTE group ($11,120 vs $1,262, cost difference: $9,858 [€6,733]; 95% CI= $9,081-$10,476). In conclusion, in this large matched-cohort study, recurrent VTE patients had significantly higher risk of complications and health care costs compared to no-recurrent VTE patients.Note: Parts of this manuscript were presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting 2012, October 21–24, Hollywood, Florida and at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting 2013, May 18–22, New Orleans, LA, USA.

scholarly journals Direct Health Care Costs of Treating Seasonal Affective Disorder: A Comparison of Light Therapy and Fluoxetine

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Amy Cheung ◽  
Carolyn Dewa ◽  
Erin E. Michalak ◽  
Gina Browne ◽  
Anthony Levitt ◽  
...  
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Mental Health Care ◽  
Affective Disorder ◽  
Health Care Costs ◽  
Seasonal Affective Disorder ◽  
Light Therapy ◽  
Major Depressive Episodes ◽  
Depressive Episodes ◽  
Care Costs

Objective.To compare the direct mental health care costs between individuals with Seasonal Affective Disorder randomized to either fluoxetine or light therapy.Methods.Data from the CANSAD study was used. CANSAD was an 8-week multicentre double-blind study that randomized participants to receive either light therapy plus placebo capsules or placebo light therapy plus fluoxetine. Participants were aged 18–65 who met criteria for major depressive episodes with a seasonal (winter) pattern. Mental health care service use was collected for each subject for 4 weeks prior to the start of treatment and for 4 weeks prior to the end of treatment. All direct mental health care services costs were analysed, including inpatient and outpatient services, investigations, and medications.Results.The difference in mental health costs was significantly higher after treatment for the light therapy group compared to the medication group—a difference of $111.25 (z=−3.77,P=0.000). However, when the amortized cost of the light box was taken into the account, the groups were switched with the fluoxetine group incurring greater direct care costs—a difference of $75.41 (z=−2.635,P=0.008).Conclusion.The results suggest that individuals treated with medication had significantly less mental health care cost after-treatment compared to those treated with light therapy.

Criminal Justice and Behavioral Health Care Costs of Mental Health Court Participants: A Six-Year Study

2014 ◽  
Vol 65 (9) ◽  
pp. 1100-1104 ◽  
Author(s):  
Henry J. Steadman ◽  
Lisa Callahan ◽  
Pamela Clark Robbins ◽  
Roumen Vesselinov ◽  
Thomas G. McGuire ◽  
...  
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Criminal Justice ◽  
Behavioral Health ◽  
Health Care Costs ◽  
Behavioral Health Care ◽  
Mental Health Court ◽  
Care Costs

Government Resources on Mental Health

2020 ◽  
Vol 35 (12) ◽  
pp. 573-573
Author(s):  
Paul Baldwin
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Clinical Research ◽  
Health Care Costs ◽  
Health Care Services ◽  
Disease Prevalence ◽  
Statistical Information ◽  
Care Services ◽  
Care Costs

State and federal governments collect massive amounts of data, both in their role as sponsors of research and as payers for an increasing share of health care services. The information available includes definitive clinical research as well as statistical information about disease prevalence and contribution to health care costs.

scholarly journals How Much Do Mental Health and Substance Use/Addiction Affect Use of General Medical Services? Extent of Use, Reason for Use, and Associated Costs

2016 ◽  
Vol 62 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Kathryn Graham ◽  
Joyce Cheng ◽  
Sharon Bernards ◽  
Samantha Wells ◽  
Jürgen Rehm ◽  
...  
Keyword(s):  
Mental Health ◽  
Primary Care ◽  
Health Care ◽  
Substance Use ◽  
Health Care Costs ◽  
Emergency Departments ◽  
Primary Care Physicians ◽  
Service Use ◽  
Cross Sectional ◽  
Care Costs

Objective: To measure service use and costs associated with health care for patients with mental health (MH) and substance use/addiction (SA) problems. Methods: A 5-year cross-sectional study (2007-2012) of administrative health care data was conducted (average annual sample size = 123,235 adults aged >18 years who had a valid Ontario health care number and used at least 1 service during the year; 55% female). We assessed average annual use of primary care, emergency departments and hospitals, and overall health care costs for patients identified as having MH only, SA only, co-occurring MH and SA problems (MH+SA), and no MH and/or SA (MH/SA) problems. Total visits/admissions and total non-MH/SA visits (i.e., excluding MH/SA visits) were regressed separately on MH, SA, and MH+SA cases compared to non-MH/SA cases using the 2011-2012 sample ( N = 123,331), controlling for age and sex. Results: Compared to non-MH/SA patients, MH/SA patients were significantly ( P < 0.001) more likely to visit primary care physicians (1.82 times as many visits for MH-only patients, 4.24 for SA, and 5.59 for MH+SA), use emergency departments (odds, 1.53 [MH], 3.79 [SA], 5.94 [MH+SA]), and be hospitalized (odds, 1.59 [MH], 4.10 [SA], 7.82 [MH+SA]). MH/SA patients were also significantly more likely than non-MH/SA patients to have non-MH/SA-related visits and accounted for 20% of the sample but over 30% of health care costs. Conclusions: MH and SA are core issues for all health care settings. MH/SA patients use more services overall and for non-MH/SA issues, with especially high use and costs for MH+SA patients.

The impact of a history of poor mental health on health care costs in the perinatal period

2018 ◽  
Vol 22 (4) ◽  
pp. 467-473 ◽  
Author(s):  
Catherine Chojenta ◽  
Jananie William ◽  
Michael A. Martin ◽  
Julie Byles ◽  
Deborah Loxton
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Health Care Costs ◽  
Perinatal Period ◽  
Poor Mental Health ◽  
History Of ◽  
The Impact ◽  
Care Costs
Sign in / Sign up

Export Citation Format

Share Document